1-8. (canceled)
9. A method of preventing or treating for a thrombus- or embolus-associated disease comprising administering to a subject at least one selected from the group consisting of clopidogrel and its pharmaceutically acceptable salts and at least one selected from the group consisting of icosapentaenoic acid as well as its pharmaceutically acceptable salts and esters to be applied in combination as an active ingredient.
10. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein said subject is suffering from a disease or condition with vascular endothelial cell damage.
11. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 10, wherein said disease or condition with vascular endothelial cell damage is a disease or condition which includes at least one symptom selected from the group consisting of high glycated-protein (or AGE) levels, diabetes, hyperglycemia, diabetic complications, arteriosclerosis obliterans (ASO) complicated with diabetes, high ox-LDL levels, hyperlipidemia involving high ox-LDL levels, and inflammation marker abnormality.
12. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein said subject is suffering from a disease or condition whose amelioration requires suppression of platelet aggregation in spite of a risk of bleeding.
13. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein said subject is selected from the group consisting of a subject having undergone revascularization and a subject with history of stroke.
14. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein said thrombus- or embolus-associated disease comprises at least one selected from the group consisting of thrombosis, embolism, cardiovascular death, fatal myocardial infarction, sudden cardiac death, non-fatal myocardial infarction, recurrence of myocardial infarction, angina pectoris decubitus, unstable angina pectoris, transient ischemic attack, congestive heart failure, new onset of exertional angina pectoris, destabilization of angina pectoris, ischemic heart disease, postoperative restenosis after cardiac revascularization, cardiovascular events occurring in an unstable phase after cardiac revascularization, cardiovascular events in a patient beyond an unstable phase after cardiac revascularization, progression of atherosclerosis, stroke, recurrence of stroke in a patient with history of stroke, recurrence after an ischemic cerebrovascular accident, consciousness disorder or nervous symptoms caused by a cerebrovascular accident, cerebral infarction, transient cerebral ischemic attack, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, lacunar infarct, syncope, ulcers, pain and cryesthesia associated with arteriosclerosis obliterans, or thrombotic andor atherothrombotic events occurring in myocardial infarction, stroke, ischemic cerebrovascular accidents, peripheral arterial diseases, acute coronary syndrome and non-ST-elevation acute coronary syndrome (unstable angina pectoris or non-Q-wave myocardial infarction).
15. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein a dose ratio of clopidogrel sulfate to ethyl icosapentate is 1:10 to 1:80.
16. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein said composition is a composite formulation of clopidogrel sulfate and ethyl icosapentate.
17. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein said composition further comprises an agent selected from the group consisting of aspirin and HMG-CoA RI.
18. The method of preventing or treating for a thrombus- or embolus-associated disease according to claim 9, wherein said composition is applied as a platelet aggregation inhibitor.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An analysis tool, comprising:
a substrate comprising a plurality of nano-sized light emitters configured to function as energy donors of a non-radiative energy transfer process when excited by an electric field;
one or more binding agents conjugated to each nano-sized light emitter; and
readout circuitry configured to determine the rate of non-radiative energy transfer between said the nano-sized light emitters and one or more non-radiative energy transfer acceptors.
2. The analysis tool of claim 1, wherein the plurality of nano-sized light emitters comprise quantum wells.
3. The analysis tool of claim 1, wherein the one or more binding agents comprise antibodies that undergo a change in conformation when bound to a specific analyte such that the distance between the respective non-radiative energy transfer acceptor and the respective nano-sized light emitter changes.
4. The analysis tool of claim 1, wherein the one or more binding agents have at least a first conformation in the presence of an analyte and a second conformation in the absence of the analyte and wherein non-radiative energy transfer takes place between the nano-sized light emitters and the non-radiateive energy transfer acceptors at a different rate for the first and second conformations.
5. The analysis tool of claim 1, comprising electrical pumping circuitry configured to generate the electrical field.
6. The analysis tool of claim 1, wherein the readout circuitry is configured to measure electrical potentials.
7. The analysis tool of claim 1, wherein the one or more binding agents bind to at least one specifc analyte.
8. The analysis tool of claim 1, wherein each binding agent is labeled with the non-radiative energy transfer acceptors.
9. An analysis tool, comprising:
a substrate comprising a plurality of nano-sized light emitters configured to function as energy donors of a non-radiative energy transfer process when excited by an electric field;
a plurality of quantum dots conjugated to the substrate;
one or more binding agents conjugated to each quantum dot; and
readout circuitry configured to determine the rate of non-radiative energy transfer between the nano-sized light emitters and the quantum dots andor between the quantum dots and one or more non-radiative energy transfer acceptors.
10. The analysis tool of claim 9, wherein the plurality of nano-sized light emitters comprise quantum wells.
11. The analysis tool of claim 9, wherein the one or more binding agents comprise antibodies that undergo a change in conformation when bound to a specific analyte such that the distance between the respective non-radiative energy transfer acceptor and a respective quantum dot changes.
12. The analysis tool of claim 9, wherein the one or more binding agents have at least a first conformation in the presence of an analyte and a second confromation in the absence of the analyte and wherein non-radiative energy transfer takes place between the quantum dots and the non-radiateive energy transfer acceptors at a different rate for the first and second conformations.
13. The analysis tool of claim 9, comprising electrical pumping circuitry configured to generate the electrical field.
14. The analysis tool of claim 9, wherein the readout circuitry is configured to measure electrical potentials.
15. The analysis tool of claim 9, wherein the one or more binding agents bind to at least one specifc analyte.
16. The analysis tool of claim 9, wherein each binding agent is labeled with the non-radiative energy transfer acceptors.
17. A method of detecting analytes, comprising the steps of:
providing a substrate comprising one or more light emitter structures configured to function as energy donors of a non-radiative energy transfer process when excited by an electric field, wherein one or more quantum dots are associated with each light emitter structure, and wherein the one or more quantum dots are conjugated to binding agents labeled with one or more non-radiative energy transfer acceptors;
determining a first rate of non-radiative energy transfer from the quantum dots to the non-radiative energy transfer acceptors;
exposing the binding agents to a sample containing one or more analytes that bind to the binding agents such that, when the binding agents bind to the one or more analytes, the binding agents undergo a conformational change that alters the distance between the respective non-radiative energy transfer acceptors and the respective quantum dot; and
determining a second rate of non-radiative energy transfer from the quantum dots to the non-radiative energy transfer acceptors.
18. The method of claim 17, wherein determining the rates of non-radiative energy transfer comprises measuring electrical potentials.
19. The method of claim 17, comprising applying an electrical field to the one or more light emitter structures to stimulate the non-radiative transfer of energy from the one or more light emitter structures to the respective quantum dots.
20. The method of claim 17, wherein the sample comprises one or more of a blood sample, a tissue sample, or an environmental sample.
21. A method of detecting analytes, comprising the steps of:
providing a substrate comprising one or more light emitter structures configured to function as energy donors of a non-radiative energy transfer process when excited by an electric field, wherein the one or more light emitter structures are conjugated to binding agents labeled with one or more non-radiative energy transfer acceptors;
determining a first rate of non-radiative energy transfer from the light emitter structures to the non-radiative energy transfer acceptors;
exposing the binding agents to a sample containing one or more analytes that bind to the binding agents such that, when the binding agents bind to the one or more analytes, the binding agents undergo a conformational change that alters the distance between the respective non-radiative energy transfer acceptors and the respective light emitter structure; and
determining a second rate of non-radiative energy transfer from the light emitter structures to the non-radiative energy transfer acceptors.
22. The method of claim 21, wherein determining the rates of non-radiative energy transfer comprises measuring electrical potentials.
23. The method of claim 21, comprising applying an electrical field to the one or more light emitter structures to stimulate the non-radiative transfer of energy from the one or more light emitter structures to the respective non-radiative energy transfer acceptors.
24. The method of claim 21, wherein the sample comprises one or more of a blood sample, a tissue sample, or an environmental sample.
25. A circuit comprising:
a pump pathway connected to at least one light emitter such that, when current passes through the pump pathway, an electrical field stimulates the non-radiative transfer of energy from the light emitter to a quantum dot or to a non-radiative energy transfer acceptor;
a readout pathway connected to at least one light emitter such that, when current passes through the readout pathway, the changes in the electrical potential attributable to the non-radiative transfer of energy to the quantum dot or to the non-radiative energy transfer acceptor are measured; and
a switch configured to switch between the pump pathway and the readout pathway.